Nutex Health Inc. announces a delay in filing its 2025 second quarter financial statements due to non-cash accounting adjustments related to stock-based compensation.
The company provided preliminary financial results for the three and six months ended June 30, 2025 and announced a stock repurchase program of up to $25 million.
Total revenue for the three months ended June 30, 2025 was $244.0 million, a significant increase from the same period in 2024.
Revenue Growth
Total revenue increased by 220.7% in the three months ended June 30, 2025 compared to the same period in 2024.
Gross Profit Margin
Gross profit margin improved to 51.2% in the three months ended June 30, 2025 compared to 29.7% in 2024.
Hospital Visits
Total visits at the Hospital Division increased by 10.6% in the three months ended June 30, 2025 compared to 2024.
Total Assets
As of June 30, 2025, the Company had total assets of $855.1 million, including cash of $96.6 million.
Stock Repurchase Program
The Board of Directors authorized a stock repurchase program of up to $25.0 million to increase shareholder value and offset dilution from future issuances.
- The delay in filing the financial statements indicates challenges related to stock-based compensation accounting adjustments.
- The significant revenue growth in the second quarter of 2025 showcases the positive performance of Nutex Health Inc.
- The stock repurchase program reflects the company's commitment to enhancing shareholder value and managing stock compensation obligations.
Despite the delay in filing, Nutex Health Inc.'s financial performance for the second quarter of 2025 demonstrates robust growth and financial stability. The stock repurchase program further highlights the company's proactive approach to enhancing shareholder value.